1-8 of 8
Linda Kessler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia

Kathryn Kimi Shimamoto, Arda Arda Karaoglu, Zachary Chan, Giorgia Giordano, Bartholomew Eisfelder, Jason Xiaojun Cheng, Hamed Youshanlouei, Syed Shah, Anand Ashwin Patel, Adam S. Duvall, Francis Burrows, Linda Kessler, Michael W Drazer, Olatoyosi Odenike, Michael J. Thirman, Wendy Stock, Caner Saygin
Journal: Blood
Blood (2024) 144 (Supplement 1): 1452.
https://doi.org/10.1182/blood-2024-201741
Published: 2024
Journal Articles

Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Sandhya Dhiman, Md. Hafiz Uddin, Vikram Dhillon, Jeff Justin Aguilar, Amro Aboukameel, Husain Khan, Sahar Bannoura, Jay Yang, Gregory Dyson, Steven Buck, Asfar Azmi, Lisa Polin, Francis Burrows, Linda Kessler, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian
Journal: Blood
Blood (2024) 144 (Supplement 1): 2768.
https://doi.org/10.1182/blood-2024-206075
Published: 2024
Journal Articles

The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax

Johanna Rausch, Margarita M. Dzama, Nadezda Dolgikh, Hanna Stiller, Stephan Bohl, Catharina Lahrmann, Kerstin Kunz, Linda Kessler, Hakim Echchannaoui, Chun-Wei David Chen, Thomas Kindler, Francis Burrows, Matthias Theobald, Daniel Sasca, Scott A. Armstrong, Michael Kuehn
Journal: Blood
Blood (2022) 140 (Supplement 1): 6226–6227.
https://doi.org/10.1182/blood-2022-167566
Published: 2022
Journal Articles

Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A -Rearranged Acute Lymphoblastic Leukemia

Catherine D Falkenstein, Lisa M Niswander, Linda Kessler, Blake Tomkinson, Francis Burrows, Sarah K Tasian
Journal: Blood
Blood (2022) 140 (Supplement 1): 3491–3492.
https://doi.org/10.1182/blood-2022-157225
Published: 2022
Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Francine M. Foss, MD, Won-Seog Kim, MD PhD, Eric Jacobsen, MD, Maria de Fatima De La Cruz, MD, Dolores Caballero, MD PhD, Ranjana H Advani, MD, Jose Maria Roncero, MD, Raquel de Oña, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, Maria Jose Terol, Eva Domingo-Domenech, MD, Miguel A. Piris, Marta Rodriguez, James Bolognese, PhD, Linda Kessler, BA, Vishnu Mishra, PhD, Robert Curry, BA, MBA, Michael Kurman, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 468.
https://doi.org/10.1182/blood-2019-128513
Published: 2019
Journal Articles

Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients

Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Vishnu Mishra, PhD, Matthew R Janes, PhD, Linda Kessler, BA
Journal: Blood
Blood (2018) 132 (Supplement 1): 5349.
https://doi.org/10.1182/blood-2018-99-116969
Published: 2018
Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Matthew R Janes, PhD, Linda Kessler, BA, Azra Raza, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3957.
https://doi.org/10.1182/blood.V130.Suppl_1.3957.3957
Published: 2017
Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E Witzig, MD, Lubomir Sokol, MD PhD, Eric Jacobsen, MD, Ranjana H. Advani, MD, Francine M Foss, MD, Rufino Mondejar, PhD, Miguel Angel Piris, PhDMD, James Bolognese, PhD, Francis Burrows, PhD, Linda Kessler, BA, Karen Bracken, MHS, Vishnu Mishra, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2788.
https://doi.org/10.1182/blood.V130.Suppl_1.2788.2788
Published: 2017